Simvastatin-romidepsin combination kills bladder cancer cells synergistically

Simvastatin-romidepsin combination kills bladder cancer cells synergistically

The HMG-CoA reductase inhibitor simvastatin activates AMP-activated protein kinase (AMPK) and thereby induces histone acetylation. We postulated that combining simvastatin with the histone deacetylase (HDAC) inhibitor romidepsin would kill bladder cancer cells by inducing histone acetylation coopera...

Full description

Bibliographic Details
Main Authors: Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:Translational Oncology
Subjects:
Romidepsin
Simvastatin
AMP-activated protein kinase (AMPK)
Endoplasmic reticulum (ER) stress
Histone acetylation
Peroxisome proliferator-activated receptor (PPAR) γ
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321001467

Internet

http://www.sciencedirect.com/science/article/pii/S1936523321001467

Similar Items